Please note: This website includes an accessibility system. Press Control-F11 to adjust the website to the visually impaired who are using a screen reader; Press Control-F10 to open an accessibility menu.

by

CTech 24/7

More stories in CTech

Mylan

17 stories about Mylan

Credit Line and Bonds: Teva's Financial Catch
12.08.19|Uri Tal-TeneAt first glance, Teva’s second quarter reports provided little cause for drama. The small print reveals a very different story
Copaxone-Competitor Developer Mapi Pharma Gets Funding for Jerusalem Plant
19.03.19|Lilach BaumerThe clinical-stage company develops more efficient versions of existing successful drugs, including a long-acting version of Teva's multiple sclerosis cash cow
Teva, Mylan Drop on Announcement of Epinephrine Injector Rival
09.12.18|Lilach BaumerNovartis’ U.S. division Sandoz announced a planned release for early 2019. The company will sell its drug, which lacks the EpiPen’s auto-injector, for $250 a pair out of pocket, compared to Mylan and Teva’s $300
Teva’s EpiPen Won’t Hit U.S. Market in Time for School Year, Report Says
26.08.18|Dror ReichThe Israeli drugmaker received approval for a first generic version of Mylan’s auto-injector earlier this month
Teva Wins FDA Approval for First Generic EpiPen
19.08.18|Lilach BaumerEpiPens were sold for less than $60 when Mylan acquired the injectors in 2007. Market Monopoly enabled the company to hike its price up to around $300 a unit today
Court Rules Allergan Can't Use Indian Tribe Deal to Protect Patents
23.07.18|CTechIn September 2017, Allergan transferred six of its patents for blockbuster dry eye drug Restasis to the St. Regis Mohawk Tribe, hoping to protect the patents under the principle of sovereign immunity
Mylan Cuts Price of Generic Copaxone Offering by 60%
11.07.18|Lilach BaumerMylan has achieved a 15%-20% market share in the U.S. since launching its generic version in late 2017 with a monthly price tag of $5,000, compared to Teva's $5,800
CTech’s Daily Israeli Tech News Roundup
17.12.17|CTechTeva might have been better off as a smaller company, new CEO says. Tel Aviv airport, stock market open as in support of Teva employees ends. A new blockchain powered juggernaut stock arrives on the Tel Aviv Stock Exchange
Teva Wants to Be Like Mylan: Agile, Lean and Profitable
17.12.17|Uri Tal-TenneThe cost-cutting plan revealed Thursday by Teva CEO Kåre Schultz showcases an intention to transform Teva into a lean and efficient generic drug company, much like main competitor Mylan
CTech’s Daily Israeli Tech News Roundup
26.11.17|CTechAmazon plans to set up a shipping center in Israel. Israeli parliamentarian criticizes Israeli arms export policy.
Mylan's Chairman was Right
26.11.17|Sophie ShulmanIn a 2015 letter, Robert J. Coury forecasted Teva’s current troubles
Investors Cheer as Mylan Plans to Delist from Israeli Stock Exchange
12.11.17|Uri Tal-Tenne and Dror ReichMylan is currently the highest valued company on the TASE at $18.5 billion
With New CEO in Seat, Teva Lowers Outlook
02.11.17|Lilach Baumer and Dror ReichOutlook reflects an earlier than expected launch of a generic competitor to Teva’s multiple sclerosis drug Copaxone
Teva's Blockbuster Drug Takes Another Generic Blow
26.10.17|Lilach BaumerMylan and European Partner Synthon won U.K. patent case related to Teva's Copaxone
Teva Loses Copaxone Market Exclusivity
04.10.17|Lilach BaumerRival Mylan received FDA approval for its generic versions of Copaxone, Teva’s flagship drug
U.S. Congress to Investigate Rising Multiple Sclerosis Drug Prices
21.08.17|Dror ReichTwo Congressmen are looking into the rising MS drug prices of seven pharmaceutical companies
With Bloated Debt, Teva Looks to Sell Assets
10.08.17|Eli Shimony and Gil KalianThe generic drugmaker said it is looking to sell Medis, an Iceland-based company it bought in 2016

About CTech Terms of Use Privacy Policy

Back to Top